Cypherpunk Technologies
Open
$0.78
Prev. Close
$0.79
High
$0.78
Low
$0.77
Market Snapshot
$70.71M
-1.2
-1.84
6
Cypherpunk Technologies, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted and immuno-oncology therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 6 full-time employees. The company went IPO on 2017-01-24. The firm focuses on the development of sirexatamab and FL-501 to treat patients with cancer. Zcash is a privacy-preserving blockchains, launched as a fork of Bitcoin with advanced cryptography that enables selective transparency. Zcash has introduced privacy technology through the use of zero-knowledge proofs (zk-SNARKs), allowing transactions to be verified without revealing sender, receiver, or amount. FL-501 is a potential class antibody designed to neutralize GDF-15 and prevent the binding to its receptor. sirexatamab (DKN-01), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. Sirexatamab is being developed in patients with esophagogastric, gynecologic, and colorectal cancers.
Cypherpunk Technologies reported a quarterly loss of $0.46 per share, but its stock experienced significant interest, surging 24.6% amid recent sell ratings.
Cypherpunk Technologies, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted and immuno-oncology therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 6 full-time employees. The company went IPO on 2017-01-24. The firm focuses on the development of sirexatamab and FL-501 to treat patients with cancer. Zcash is a privacy-preserving blockchains, launched as a fork of Bitcoin with advanced cryptography that enables selective transparency. Zcash has introduced privacy technology through the use of zero-knowledge proofs (zk-SNARKs), allowing transactions to be verified without revealing sender, receiver, or amount. FL-501 is a potential class antibody designed to neutralize GDF-15 and prevent the binding to its receptor. sirexatamab (DKN-01), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. Sirexatamab is being developed in patients with esophagogastric, gynecologic, and colorectal cancers.
Recently from Cashu
Cypherpunk Technologies Invests $5 Million in Zcash Development for Enhanced Privacy Solutions
Cypherpunk Technologies Strengthens Commitment to Privacy with Investment in Zcash Development Cypherpunk Technologies Inc. announces a significant $5 million investment in the Zcash Open Development…
Cypherpunk Technologies Enhances Crypto Privacy Solutions with Open-Source Initiatives and Education
Cypherpunk Technologies Strengthens Position in Crypto Privacy Solutions through Strategic Initiative Cypherpunk Technologies, a front-runner in the realm of digital privacy advocacy, is actively enha…
Please provide the content you would like summarized, and I'll create a title for you!
I'm sorry, but it seems like you haven't provided the specific content you'd like summarized. Please provide the text, and I'll be happy to help you with the summary!
Cypherpunk Technologies Appoints Arjun Khemani as Strategic Advisor to Enhance Privacy Leadership
Cypherpunk Technologies Bolsters Leadership with Strategic Advisor Appointment Cypherpunk Technologies Inc., a privacy technology innovator based in Cambridge, Massachusetts, strengthens its leadershi…